Tumoral angiogenesis: review of the literature.

Primary tabs

field_vote: 
Average: 5 (1 vote)
Publication type: 
Therapeutic intervention: 
Disease(s): 
References: 

Cancer Invest. 2008 Feb;26(1):104-8.

Tumoral angiogenesis: review of the literature.
 
Khosravi Shahi P, Fernández Pineda I.

Servicio de Oncología, Médica, Hospital General Universitario, Gregorio Marañón, Madrid, Spain.

Tumoral
angiogenesis is necessary for the growth of neoplasms and the
production of metastasis. The vascular endothelial growth factor (VEGF)
is a homodimeric heparin-binding glycoprotein that binds to
VEGF-receptors and can induce endothelial cell mitosis, invasion, and
eventually capillary tube formation. Bevacizumab, a humanized
monoclonal antibody against VEGF, inhibits tumoral angiogenesis and may
also improve the delivery of chemotherapy to the tumor mass. Some new
antiangiogenic agents, called multi-kinase inhibitors (sorafenib and
sunitinib), have also activity against other receptors, such as
epidermal growth factor-receptor or platelet-derived growth
factor-receptor. A new schedule of treatment (metronomic chemotherapy)
also has antiangiogenic activity.